search
Back to results

Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling

Primary Purpose

Skin Laxity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dermal Handpiece
Sponsored by
University of Texas Southwestern Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Skin Laxity

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male and female adults between ages 21-70 years of age.
  • Desire skin laxity lift of the submental region.
  • Confirmed BMI ≤ 35.
  • Subjects who can read, understand, and sign the Informed Consent Form.
  • Subjects willing and able to comply with all study requirements.
  • Fitzpatrick skin type I-VI.
  • Submental fat graded by the Investigator as ≥ 1 using the Clinician-Reported Submental Fat Rating Scale
  • Subject is willing not to undergo any type of aesthetic procedure that could confound the study device treatment effects until he/she completes the study.

Exclusion Criteria:

  • Active localized or systemic infections, that may alter wound healing.
  • Immunocompromised subjects.
  • Subjects with coagulation disorder.
  • History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs).
  • Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study).
  • Excessive skin laxity on the submental and neck (Submental Skin Laxity Grade: SMSLG 4, Appendix E), or other anatomical feature for which reduction in SMF which may, in the judgment of the investigator, result in an aesthetically unacceptable outcome.
  • Scarring in areas to be treated.
  • Tattoos in the treatment areas to be treated.
  • Significant open facial wounds or lesions.
  • Severe or cystic acne in treatment areas.
  • Current active smoker.
  • Use of Accutane (Isotretinoin) within the past 6 months.
  • Use of topical retinoids within 48 hours.
  • Use of prescription anticoagulants.
  • Pacemaker or internal defibrillator.
  • History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme dry and fragile skin).
  • Subjects on current oral corticosteroid therapy or within the past 6 months
  • Metal implants in the treatment area.
  • In the opinion of the investigator, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits.
  • Subjects with a history of radiation therapy to the treatment area.
  • Subject has a history of allergy to lidocaine or ester-based local anesthetics.
  • Subjects with significant cardiac history or rhythm disturbance who may be unable to tolerate lidocaine with epinephrine.
  • Subjects with any skin pathology or condition in the treatment area that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments (e.g. psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation).
  • Subjects who are unwilling to shave excessive hair in the treatment area that might influence or impair evaluation in the opinion of the Investigator.
  • Subjects have undergone skin resurfacing or tightening treatments in the treatment area over the past year.
  • Subjects have undergone dermatological treatments such as fillers and neurotoxins for the past 6 months in the treatment area.
  • Subjects have undergone laser and light treatments in the treatment area over the past 3 months.
  • Subjects have undergone superficial peel or microdermabrasion within 4 weeks.

Sites / Locations

  • UT Southwestern Medical Center- Dept of Plastic Surgery

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single Group

Arm Description

All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.

Outcomes

Primary Outcome Measures

Volume change in the submental region
Improvement will be assessed by change in the surface area assessments of baseline (pre-procedure) and 6 months (post-procedure).
Incidence, severity, and relatedness of adverse events
The number and level of severity of adverse events after treatment. An assessment will be made by the PI to determine if the adverse event is related to the study device and/or procedure.

Secondary Outcome Measures

Improvement in overall lift: H2 and Stand Up Vectra
Blinded evaluators will be asked to evaluate photographs obtained via the H2 3D Imaging System and Stand Up Vectra (Canfield) of the subjects at baseline (pre-treatment) and 6 months (post-treatment).
Improvement in Assessments: Global Aesthetic Improvement Score
Blinded reviewers will assessment and score using a 5-point Global Aesthetic Improvement Score (1=Very Much Improved, 5= worse)
Subjects Assessment of Pain: Numerical Pain Rating Scale
The subjects' assessment of pain will be completed using an 11-point Numerical Pain Scale (0= No pain, 10= Extreme pain)
Improvement in Non-invasive Measurements: Aquaflux
Skin texture and laxity will be assessed using non invasive skin measurements. Biox Aquaflux- will be used to measure transepidermal water loss.
Improvement in Non-invasive Measurements: OCT
Skin texture and laxity will be assessed using non invasive skin measurements. Optical coherence tomography will be used to topographical and histological images of the skin.
Improvement in Non-invasive Measurements : BTC2000
Skin texture and laxity will be assessed using non invasive skin measurements. BTC2000- will be used to measure skin laxity values of the skin.
Improvement in Non-invasive Measurements : BTC2000
Skin texture and laxity will be assessed using non invasive skin measurements. BTC2000- will be used to measure elasticity of the skin.

Full Information

First Posted
July 8, 2020
Last Updated
January 4, 2023
Sponsor
University of Texas Southwestern Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04477187
Brief Title
Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
Official Title
Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
October 1, 2020 (Actual)
Primary Completion Date
June 13, 2022 (Actual)
Study Completion Date
December 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Texas Southwestern Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and efficacy of bipolar fractional radiofrequency treatment via use of the Profound System to achieve skin tightening and contour change in lax submental (beneath the chin) tissue.
Detailed Description
This is a single-center, unblinded, non-randomized, non-controlled study designed to follow a total of up to 15 qualified and consenting subjects to receive one bipolar fractional radiofrequency microneedling treatment under an IRB approved protocol. Up to 15 subjects will be enrolled and treated at UT Southwestern in the Department of Plastic Surgery. Subjects will be identified from the clinical practice of Dr. Jeffrey Kenkel, Department of Plastic Surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Laxity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single Group
Arm Type
Experimental
Arm Description
All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.
Intervention Type
Device
Intervention Name(s)
Dermal Handpiece
Intervention Description
Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
Primary Outcome Measure Information:
Title
Volume change in the submental region
Description
Improvement will be assessed by change in the surface area assessments of baseline (pre-procedure) and 6 months (post-procedure).
Time Frame
Baseline - 6 Months (Day 180)
Title
Incidence, severity, and relatedness of adverse events
Description
The number and level of severity of adverse events after treatment. An assessment will be made by the PI to determine if the adverse event is related to the study device and/or procedure.
Time Frame
Baseline - 6 Months (Day 180)
Secondary Outcome Measure Information:
Title
Improvement in overall lift: H2 and Stand Up Vectra
Description
Blinded evaluators will be asked to evaluate photographs obtained via the H2 3D Imaging System and Stand Up Vectra (Canfield) of the subjects at baseline (pre-treatment) and 6 months (post-treatment).
Time Frame
Baseline - 6 Months (Day 180)
Title
Improvement in Assessments: Global Aesthetic Improvement Score
Description
Blinded reviewers will assessment and score using a 5-point Global Aesthetic Improvement Score (1=Very Much Improved, 5= worse)
Time Frame
Baseline - 6 Months (Day 180)
Title
Subjects Assessment of Pain: Numerical Pain Rating Scale
Description
The subjects' assessment of pain will be completed using an 11-point Numerical Pain Scale (0= No pain, 10= Extreme pain)
Time Frame
Through study completion, an average of 6 Months (Day 180)
Title
Improvement in Non-invasive Measurements: Aquaflux
Description
Skin texture and laxity will be assessed using non invasive skin measurements. Biox Aquaflux- will be used to measure transepidermal water loss.
Time Frame
Baseline - 6 Months (Day 180)
Title
Improvement in Non-invasive Measurements: OCT
Description
Skin texture and laxity will be assessed using non invasive skin measurements. Optical coherence tomography will be used to topographical and histological images of the skin.
Time Frame
Baseline - 6 Months (Day 180)
Title
Improvement in Non-invasive Measurements : BTC2000
Description
Skin texture and laxity will be assessed using non invasive skin measurements. BTC2000- will be used to measure skin laxity values of the skin.
Time Frame
Baseline - 6 Months (Day 180)
Title
Improvement in Non-invasive Measurements : BTC2000
Description
Skin texture and laxity will be assessed using non invasive skin measurements. BTC2000- will be used to measure elasticity of the skin.
Time Frame
Baseline - 6 Months (Day 180)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male and female adults between ages 21-70 years of age. Desire skin laxity lift of the submental region. Confirmed BMI ≤ 35. Subjects who can read, understand, and sign the Informed Consent Form. Subjects willing and able to comply with all study requirements. Fitzpatrick skin type I-VI. Submental fat graded by the Investigator as ≥ 1 using the Clinician-Reported Submental Fat Rating Scale Subject is willing not to undergo any type of aesthetic procedure that could confound the study device treatment effects until he/she completes the study. Exclusion Criteria: Active localized or systemic infections, that may alter wound healing. Immunocompromised subjects. Subjects with coagulation disorder. History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs). Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study). Excessive skin laxity on the submental and neck (Submental Skin Laxity Grade: SMSLG 4, Appendix E), or other anatomical feature for which reduction in SMF which may, in the judgment of the investigator, result in an aesthetically unacceptable outcome. Scarring in areas to be treated. Tattoos in the treatment areas to be treated. Significant open facial wounds or lesions. Severe or cystic acne in treatment areas. Current active smoker. Use of Accutane (Isotretinoin) within the past 6 months. Use of topical retinoids within 48 hours. Use of prescription anticoagulants. Pacemaker or internal defibrillator. History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme dry and fragile skin). Subjects on current oral corticosteroid therapy or within the past 6 months Metal implants in the treatment area. In the opinion of the investigator, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits. Subjects with a history of radiation therapy to the treatment area. Subject has a history of allergy to lidocaine or ester-based local anesthetics. Subjects with significant cardiac history or rhythm disturbance who may be unable to tolerate lidocaine with epinephrine. Subjects with any skin pathology or condition in the treatment area that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments (e.g. psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation). Subjects who are unwilling to shave excessive hair in the treatment area that might influence or impair evaluation in the opinion of the Investigator. Subjects have undergone skin resurfacing or tightening treatments in the treatment area over the past year. Subjects have undergone dermatological treatments such as fillers and neurotoxins for the past 6 months in the treatment area. Subjects have undergone laser and light treatments in the treatment area over the past 3 months. Subjects have undergone superficial peel or microdermabrasion within 4 weeks.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Kenkel, MD
Organizational Affiliation
UT Southwestern
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT Southwestern Medical Center- Dept of Plastic Surgery
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling

We'll reach out to this number within 24 hrs